KD-496
Phase 1Cell therapy
KD-496 is one of 86 biologic programs targeting Gastric Cancer. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
193 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Avastin
RochePhase 3
Cyramza
Eli LillyPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Adrucil
EElorac, Inc.
Phase 3
S-1
Taiho Oncology, Inc.Phase 3
Apatinib
LLaNova Medicines Zhejiang Co., Ltd.
Phase 3
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KD-496. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- PPeking University